These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30618531)

  • 1. The correlation between serum E-selectin levels and soluble interleukin-2 receptors with relation to disease activity in localized scleroderma.
    Wodok-Wieczorek K; Salwowska N; Syguła E; Wodok A; Wcisło-Dziadecka D; Bebenek K; Bergler-Czop B; Brzezińska-Wcisło L
    Postepy Dermatol Alergol; 2018 Dec; 35(6):614-619. PubMed ID: 30618531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of soluble interleukin-2 receptor. A marker of disease activity in localized scleroderma.
    Uziel Y; Krafchik BR; Feldman B; Silverman ED; Rubin LA; Laxer RM
    Arthritis Rheum; 1994 Jun; 37(6):898-901. PubMed ID: 8003062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma.
    Ihn H; Sato S; Fujimoto M; Kikuchi K; Takehara K
    Br J Dermatol; 1996 May; 134(5):843-7. PubMed ID: 8736323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble adhesion molecules and interleukin-2 receptor concentrations in patients with autoimmune chronic hepatitis.
    Simpson KJ; Jones AL; Forbes Howie A; Hayes PC
    Eur J Gastroenterol Hepatol; 1995 May; 7(5):455-60. PubMed ID: 7542148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels.
    Polisson RP; Gilkeson GS; Pyun EH; Pisetsky DS; Smith EA; Simon LS
    J Rheumatol; 1996 Apr; 23(4):654-8. PubMed ID: 8730122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble serum interleukin 2 receptors in patients with systemic sclerosis.
    Steen VD; Engel EE; Charley MR; Medsger TA
    J Rheumatol; 1996 Apr; 23(4):646-9. PubMed ID: 8730120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis.
    Majewski S; Wojas-Pelc A; Malejczyk M; Szymanska E; Jablonska S
    Acta Derm Venereol; 1999 May; 79(3):207-10. PubMed ID: 10384918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma.
    Yamane K; Ihn H; Kubo M; Yazawa N; Kikuchi K; Soma Y; Tamaki K
    J Am Acad Dermatol; 2000 Jan; 42(1 Pt 1):64-9. PubMed ID: 10607321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procalcitonin, soluble interleukin-2 receptor, and soluble E-selectin in predicting the severity of acute pancreatitis.
    Kylänpää-Bäck ML; Takala A; Kemppainen EA; Puolakkainen PA; Leppäniemi AK; Karonen SL; Orpana A; Haapiainen RK; Repo H
    Crit Care Med; 2001 Jan; 29(1):63-9. PubMed ID: 11176162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis.
    Lee YJ; Shin KC; Kang SW; Lee EB; Kim HA; Song YW
    Clin Exp Rheumatol; 2001; 19(1):69-74. PubMed ID: 11247328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating interleukin 1 beta and soluble interleukin 2 receptor: evaluation as markers of disease activity in scleroderma.
    Patrick MR; Kirkham BW; Graham M; Harrision LC
    J Rheumatol; 1995 Apr; 22(4):654-8. PubMed ID: 7791158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug.
    Kuuliala A; Leirisalo-Repo M; Möttönen T; Hannonen P; Nissilä M; Kautiainen H; Korpela M; Julkunen H; Hakola M; Repo H;
    Clin Exp Rheumatol; 2005; 23(2):243-6. PubMed ID: 15895898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of serum concentrations of the selected cytokines in patients with localized scleroderma.
    Budzyńska-Włodarczyk J; Michalska-Jakubus MM; Kowal M; Krasowska D
    Postepy Dermatol Alergol; 2016 Feb; 33(1):47-51. PubMed ID: 26985179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo.
    Caixia T; Hongwen F; Xiran L
    J Dermatol Sci; 1999 Sep; 21(1):59-62. PubMed ID: 10468193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers of endothelial cell activation and immune activation are increased in patients with severe leptospirosis and associated with disease severity.
    Goeijenbier M; Gasem MH; Meijers JC; Hartskeerl RA; Ahmed A; Goris MG; Isbandrio B; Schuller SS; Osterhaus AD; Martina BE; van Gorp EC; Nally JE; Wagenaar JF
    J Infect; 2015 Oct; 71(4):437-46. PubMed ID: 26048204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin.
    Søndergaard K; Stengaard-Pedersen K; Zachariae H; Heickendorff L; Deleuran M; Deleuran B
    Br J Rheumatol; 1998 Mar; 37(3):304-10. PubMed ID: 9566672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of soluble interleukin-2 receptor in monitoring disease relapse in patients with nasopharyngeal cancer.
    Wu LJ; Chen KY; Chi KH; Chen SY; Liang MJ; Shiau CY; Wang LW; Liu YM; Chow KC; Yen SH
    Jpn J Clin Oncol; 1998 Dec; 28(12):729-32. PubMed ID: 9879289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus.
    Doganay S; Evereklioglu C; Er H; Türköz Y; Sevinç A; Mehmet N; Savli H
    Eye (Lond); 2002 Mar; 16(2):163-70. PubMed ID: 11988817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating P- and L-selectin and T-lymphocyte activation and patients with autoimmune rheumatic diseases.
    Sfikakis PP; Charalambopoulos D; Vaiopoulos G; Mavrikakis M
    Clin Rheumatol; 1999; 18(1):28-32. PubMed ID: 10088945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma.
    Mariotti S; Barbesino G; Caturegli P; Marinò M; Manetti L; Fugazzola L; Pacini F; Pinchera A
    J Endocrinol Invest; 1994 Dec; 17(11):861-7. PubMed ID: 7745234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.